Report Summary
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
The global Efinaconazole market is valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2027, growing at a CAGR of xx% during 2021-2027. The objectives of this study are to define, segment, and project the size of the Efinaconazole market based on company, product type, end user and key regions.
This report studies the global market size of Efinaconazole in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Efinaconazole in these regions.
This research report categorizes the global Efinaconazole market by top players/brands, region, type and end user. This report also studies the global Efinaconazole market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
VIRUJ PHARMA
Valeant
Market size by Product
Purity ? 98%
Purity ? 98%
Market size by End User
Onychomycosis
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Efinaconazole market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2020, and forecast to 2027.
To understand the structure of Efinaconazole market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Efinaconazole companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Efinaconazole submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Efinaconazole are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Efinaconazole market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Efinaconazole Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Efinaconazole Market Size Growth Rate by Product
1.4.2 Purity ? 98%
1.4.3 Purity ? 98%
1.5 Market by End User
1.5.1 Global Efinaconazole Market Size Growth Rate by End User
1.5.2 Onychomycosis
1.5.3 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Efinaconazole Market Size
2.1.1 Global Efinaconazole Revenue 2017-2027
2.1.2 Global Efinaconazole Sales 2017-2027
2.2 Efinaconazole Growth Rate by Regions
2.2.1 Global Efinaconazole Sales by Regions
2.2.2 Global Efinaconazole Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Efinaconazole Sales by Manufacturers
3.1.1 Efinaconazole Sales by Manufacturers
3.1.2 Efinaconazole Sales Market Share by Manufacturers
3.1.3 Global Efinaconazole Market Concentration Ratio (CR5 and HHI)
3.2 Efinaconazole Revenue by Manufacturers
3.2.1 Efinaconazole Revenue by Manufacturers (2017-2020)
3.2.2 Efinaconazole Revenue Share by Manufacturers (2017-2020)
3.3 Efinaconazole Price by Manufacturers
3.4 Efinaconazole Manufacturing Base Distribution, Product Types
3.4.1 Efinaconazole Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Efinaconazole Product Type
3.4.3 Date of International Manufacturers Enter into Efinaconazole Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Efinaconazole Sales by Product
4.2 Global Efinaconazole Revenue by Product
4.3 Efinaconazole Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Efinaconazole Breakdown Data by End User
6 North America
6.1 North America Efinaconazole by Countries
6.1.1 North America Efinaconazole Sales by Countries
6.1.2 North America Efinaconazole Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Efinaconazole by Product
6.3 North America Efinaconazole by End User
7 Europe
7.1 Europe Efinaconazole by Countries
7.1.1 Europe Efinaconazole Sales by Countries
7.1.2 Europe Efinaconazole Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Efinaconazole by Product
7.3 Europe Efinaconazole by End User
8 Asia Pacific
8.1 Asia Pacific Efinaconazole by Countries
8.1.1 Asia Pacific Efinaconazole Sales by Countries
8.1.2 Asia Pacific Efinaconazole Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Efinaconazole by Product
8.3 Asia Pacific Efinaconazole by End User
9 Central & South America
9.1 Central & South America Efinaconazole by Countries
9.1.1 Central & South America Efinaconazole Sales by Countries
9.1.2 Central & South America Efinaconazole Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Efinaconazole by Product
9.3 Central & South America Efinaconazole by End User
10 Middle East and Africa
10.1 Middle East and Africa Efinaconazole by Countries
10.1.1 Middle East and Africa Efinaconazole Sales by Countries
10.1.2 Middle East and Africa Efinaconazole Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Efinaconazole by Product
10.3 Middle East and Africa Efinaconazole by End User
11 Company Profiles
11.1 VIRUJ PHARMA
11.1.1 VIRUJ PHARMA Company Details
11.1.2 Company Business Overview
11.1.3 VIRUJ PHARMA Efinaconazole Sales, Revenue and Gross Margin (2017-2020)
11.1.4 VIRUJ PHARMA Efinaconazole Products Offered
11.1.5 VIRUJ PHARMA Recent Development
11.2 Valeant
11.2.1 Valeant Company Details
11.2.2 Company Business Overview
11.2.3 Valeant Efinaconazole Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Valeant Efinaconazole Products Offered
11.2.5 Valeant Recent Development
12 Future Forecast
12.1 Efinaconazole Market Forecast by Regions
12.1.1 Global Efinaconazole Sales Forecast by Regions 2021-2027
12.1.2 Global Efinaconazole Revenue Forecast by Regions 2021-2027
12.2 Efinaconazole Market Forecast by Product
12.2.1 Global Efinaconazole Sales Forecast by Product 2021-2027
12.2.2 Global Efinaconazole Revenue Forecast by Product 2021-2027
12.3 Efinaconazole Market Forecast by End User
12.4 North America Efinaconazole Forecast
12.5 Europe Efinaconazole Forecast
12.6 Asia Pacific Efinaconazole Forecast
12.7 Central & South America Efinaconazole Forecast
12.8 Middle East and Africa Efinaconazole Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Efinaconazole Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
